Keyword: Novartis

News

U.S. Justices Agree to Hear Teva's Copaxone Appeal

01.04.2014 - The U.S. Supreme Court on Mar. 31 agreed to hear an appeal filed by Teva Pharmaceutical Industries in a patent fight over top-selling multiple sclerosis drug Copaxone. The move...

News

Codexis Reports Fourth Quarter and Full Year 2013 Results

12.03.2014 - Codexis, Inc. developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31...

News

Bayer, Novartis said to Eye Merck & Co consumer health unit

21.02.2014 - A handful of consumer and healthcare companies including Germany's Bayer and Switzerland's Novartis are exploring a deal for Merck & Co's consumer healthcare business, people...

News

Novartis Acquires U.S. Cancer Specialist CoStim

19.02.2014 - Swiss pharmaceuticals giant Novartis has announced plans to acquire U.S. biotech firm CoStim. The privately owned cancer therapy specialist based at Cambridge, Massachusetts...

News

Swiss Anti-Immigration Vote Could Impact Chemical Sector

11.02.2014 - Switzerland's narrow 50.3% approval of the nationalist party SVP's referendum to limit immigration on Feb. 9 could cause major staffing headaches for companies such as Novartis...

News

Novartis Said to Be Mulling a Jobs Shift to India

06.02.2014 - In a move designed to enhance its presence in India, Novartis plans to build a new business center in Hyderabad, India. However, talking to the news agency Reuters. the Swiss...

News

Fourth Ranbaxy Generics Plant Hit by FDA Ban

27.01.2014 - Indian drugmaker Ranbaxy Laboratories faces long delays and high costs in launching big-selling generic drugs in the U.S. after products from a fourth plant were banned due to...

News

J&J Petitions FDA to Require ‘Similar’ Names For Biosimilars, Biologics

10.01.2014 - Johnson & Johnson on Wednesday said it submitted a citizen petition asking that U.S. health regulators require copies of biological products to bear names that are similar and not...